BICO Group AB Class B (CLLKF) Q2 2026 Earnings Report
CLLKF Q2 2026 EPS Results
- Actual EPS
- -$0.05
- Consensus EPS
- -$0.07
- Beat/Miss
- Beat by +$0.02
- One Year Ago EPS
- -$0.26
CLLKF Q2 2026 Revenue Results
- Actual Revenue
- $34.33M
- Expected Revenue
- $34.93M
- Beat/Miss
- Missed by -$602.58K
- YoY Revenue Growth
- +3.67%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/19/2026
- Time
- Before Open
- Conference Call
- Wednesday, August 19, 2026
BICO Group AB Class B's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call combined meaningful operational and financial improvements (strong product launches, a large long-term license/supply agreement, substantial gross margin expansion, improved adjusted EBITDA margin, reductions in operating expenses and a stronger balance sheet) with persistent operational and market headwinds (project execution issues in the U.S. project business, negative operating cash flow driven by working capital movements, soft North American/academic end markets and longer sales cycles for large automation projects). Progress on commercialization and profitability is clear, but execution risk in project-based automation and short-term cash-flow/working-capital pressure leave mixed near-term visibility.
The company did not provide formal forward-looking financial guidance, but offered directional expectations and several specific metrics: Q2 sales were SEK 336m (organic growth +7% in local currencies, total growth +4%), adjusted EBITDA SEK 20m (adjusted EBITDA margin 6%, a +21 percentage-point improvement), EBITDA SEK 60m, gross margin 59% (vs 44% a year ago), consumables +10%, and operating cash flow was negative SEK 53m (driven by a net working capital change of -SEK 54m: receivables +SEK 15m, inventories +SEK 6m, payables -SEK 33m). Balance-sheet and cash metrics included cash reserves SEK 628m (SEK 57m restricted) and net cash SEK 207m (improved from net debt of -SEK 877m previously). Management expects working capital to normalize toward an industry standard of ~20% of sales over time, anticipates annualized savings of NOK 30m from the Lyon→Berlin consolidation (effects starting H2), and disclosed a Scienion deal with ~EUR 50m contracted over 10 years plus a license of EUR 10.6m to be recognized as revenue in Q3 (cash invoiced annually).
- Quarterly Revenue and Organic GrowthSales of SEK 336 million in Q2 2026, representing organic growth of 7% in local currencies and reported growth of 4% after currency headwinds.
- Significant License & Supply AgreementScienion signed long-term supply and license agreements with a combined contracted value of approximately EUR 50 million over 10 years; EUR 10.6 million of the license revenue will be recognized as revenue in Q3 per IFRS (recognized at point in time).
- Margin Expansion and Profitability ImprovementGross profit margin improved materially from 44% to 59% year-over-year. Adjusted EBITDA amounted to SEK 20 million with an adjusted EBITDA margin of 6%, an improvement of 21 percentage points versus prior year (excluding last year's SEK 40 million adjustment, adjusted EBITDA margin improved from -2.6% to 6%).
- Operational Cost Reductions and RestructuringOperating expenses decreased by 7% year-over-year. Group-wide efficiency program and a site consolidation (Lyon to Berlin) launched to drive standardization and automation, with anticipated annualized savings of NOK 30 million expected to start materializing in H2.
- Stronger Balance Sheet and Cash ReservesCash reserves of SEK 628 million at period end (SEK 57 million restricted). Management highlighted a strengthened balance sheet (citing improvement from net debt of negative SEK 877 million to net cash of SEK 207 million) and availability to pursue organic and selective bolt-on opportunities.
- Consumables and Benchtop Instrument StrengthConsumables grew by 10% in the quarter. Management reported continued strong momentum in benchtop instruments and higher share of direct sales contributing to improved product mix.
- Product Innovation and R&D ProgressTwo key launches in the quarter: Confluence AI for cell culture (licensed software feature integrated into existing systems) and G.PURE Gen 2 for automated DNA purification (claims: 10x faster, saves ~300,000 pipettes/year for a midsized lab and ~18 minutes per plate = ~4 working weeks per instrument/year). Multiple additional instrument, software and consumable launches planned.
- Commercial Leadership Transition with ContinuityBoard appointed Anders Fogelberg (current CCO) as incoming President & CEO effective Sept 1; management emphasizes continuity with continued focus on commercialization, customer engagement and profitable growth and a planned handover with outgoing CEO staying on as senior adviser for a quarter.
CLLKF Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 11, 2026 | 2026 (Q3) | 0.12- | -1.6 | ― | ― |
| Aug 19, 2026 | 2026 (Q2) | -0.07-0.05 | -0.26 | 80.31% (+0.21) | |
| Apr 29, 2026 | 2026 (Q1) | -0.10-0.16 | -0.33 | 52.74% (+0.18) | |
| Feb 18, 2026 | 2025 (Q4) | -0.05-0.08 | 0.37 | -122.47% (-0.46) | |
| Nov 04, 2025 | 2025 (Q3) | -0.10-1.60 | -0.37 | -333.38% (-1.23) | |
| Aug 19, 2025 | 2025 (Q2) | -0.12-0.26 | -0.11 | -137.38% (-0.15) | |
| Apr 29, 2025 | 2025 (Q1) | -0.13-0.33 | -0.04 | -709.88% (-0.29) | |
| Feb 19, 2025 | 2024 (Q4) | -0.020.37 | -0.87 | 142.97% (+1.24) | |
| Nov 26, 2024 | 2024 (Q3) | -0.04-0.37 | -0.1 | -269.90% (-0.27) | |
| Aug 20, 2024 | 2024 (Q2) | -0.10-0.11 | -0.81 | 86.50% (+0.70) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

